<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27943" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pseudomembranous Colitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salen</surname>
            <given-names>Philip</given-names>
          </name>
          <aff>St. Luke's University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stankewicz</surname>
            <given-names>Holly A.</given-names>
          </name>
          <aff>St. Luke's University Health Network</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Philip Salen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Holly Stankewicz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27943.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pseudomembranous colitis, a severe inflammation of the inner lining of the large intestine, manifests as an antibiotic-associated colonic inflammatory complication. The disease most commonly results from a serious Clostridium difficile infection, an increasing nosocomial issue over the last two decades. This activity reviews the cause, pathophysiology and presentation of pseudomembranous toxicity and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology pseudomembranous toxicity.</p></list-item><list-item><p>Review the evaluation of a patient with pseudomembranous toxicity.</p></list-item><list-item><p>Summarize the treatment and management options available for pseudomembranous toxicity.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care coordination and outcomes in patients with pseudomembranous toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27943&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27943">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27943.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Pseudomembranous colitis, a severe inflammation of the inner lining of the large intestine, manifests as an antibiotic-associated colonic inflammatory complication. The disease&#x000a0;most commonly results from a serious <italic toggle="yes">Clostridium difficile</italic> infection, an increasing nosocomial issue over the last two decades.<xref ref-type="bibr" rid="article-27943.r1">[1]</xref><xref ref-type="bibr" rid="article-27943.r2">[2]</xref><xref ref-type="bibr" rid="article-27943.r3">[3]</xref></p>
      </sec>
      <sec id="article-27943.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Pseudomembranous colitis results most commonly from<italic toggle="yes"> C. difficile</italic> infections; however, less common etiologies include ischemic colitis, collagenous colitis, inflammatory bowel disease, cytomegalovirus-induced colitis, vasculitis, bacterial and parasitic organisms, Behcet&#x02019;s Disease, chemotherapeutic medications, and toxins, such as heavy metal poisoning. Often considered as solely a nosocomial pathogen, <italic toggle="yes">C. difficile</italic>&#x000a0;most commonly causes diarrheal illness in the elderly with histories of antimicrobial utilization or healthcare facility stays. Other<italic toggle="yes"> C. difficile</italic> risk factors include the history of prior<italic toggle="yes"> C. difficile</italic> infection, advanced age, use of gastric acid-suppressing medications, gastrointestinal surgery, feeding tubes, immunodeficiency, chemotherapy, chronic kidney disease, and inflammatory bowel disease. The absence of risk factors does not exclude the presence of&#x000a0;<italic toggle="yes">C difficile</italic> infection.<xref ref-type="bibr" rid="article-27943.r4">[4]</xref><xref ref-type="bibr" rid="article-27943.r5">[5]</xref></p>
      </sec>
      <sec id="article-27943.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p><italic toggle="yes">C. difficile i</italic>nfections have increased over the last 20 years with almost 500,000 episodes and 29,000 associated deaths reported annually in the United States, which makes it among the most common nosocomial infections. <italic toggle="yes">C. difficile</italic> colitis in patients without antibiotic and healthcare exposure has led to the recognition of community-associated <italic toggle="yes">C difficile i</italic>nfection. The most common cause of infectious diarrhea in healthcare settings,<italic toggle="yes"> C. difficile</italic> causes substantial morbidity and can potentially result in mortality in vulnerable inpatient populations. <italic toggle="yes">C. difficile</italic> colonization occurs in 13% of hospitalized patients with stays of 2 weeks and up to 50% of patients with stays more than 4 weeks.<italic toggle="yes"> C. difficile</italic> can colonize the human colon; 2% to 5% of the healthy outpatient community will be colonized and will not manifest signs of infection.<xref ref-type="bibr" rid="article-27943.r5">[5]</xref><xref ref-type="bibr" rid="article-27943.r6">[6]</xref></p>
      </sec>
      <sec id="article-27943.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The administration of antibiotics, chemotherapeutic drugs, or immunosuppressive therapy disrupts the normal colonic biome, which allows for <italic toggle="yes">C. difficile</italic> colonization. <italic toggle="yes">C. difficile</italic> induces colitis via exotoxin production, toxin A, and toxin B. These toxins generate inflammation, colonic cell cytoskeleton disruption, and cellular death. The pseudomembranes of pseudomembranous colitis form as these toxins pathologically hyperstimulate the native immune system by drawing neutrophils to invade the colonic mucosa.<xref ref-type="bibr" rid="article-27943.r7">[7]</xref></p>
      </sec>
      <sec id="article-27943.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>An invasive test not usually performed for the initial diagnosis of<italic toggle="yes"> C. difficile</italic> or antibiotic-induced colitis, colonoscopy aids in confirming the diagnosis of pseudomembranous colitis in the presence of suggestive symptoms, negative testing, and failure to respond to conventional treatment. Colonoscopies of patients with pseudomembranous colitis demonstrate inflamed colonic mucosa characterized by raised yellowish, occasionally hemorrhagic nodules or plaques that congregate into widespread, pseudomembranes on the surface of the colonic mucosa. Up to 2 cm in diameter, these pseudomembranes&#x000a0;present in scattered diffusely among areas of normal or healthy mucosa. The most severely affected have&#x000a0;confluent pseudomembranes covering the entirety of their colonic mucosa.</p>
      </sec>
      <sec id="article-27943.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with pseudomembranous colitis most commonly&#x000a0;report symptomatic diarrhea. <italic toggle="yes">C. difficile</italic> presents in various ways. Patients may be asymptomatic carriers or present with fulminant pseudomembranous colitis with toxic megacolon. Generally, the presence of pseudomembranes indicates a more severe case of <italic toggle="yes">C. difficile</italic> infection or antibiotic-associated diarrhea. Other notable symptoms and signs include fever, abdominal cramping, and leukocytosis. Severe pseudomembranous colitis can manifest profound leukocytosis with white blood cell counts up to 100,000/mm3, hypovolemia, hypotension, protein-losing enteropathy, reactive arthritis, and toxic megacolon. About 3% to 8% of pseudomembranous colitis will develop fulminant infection including severe ileus, toxic megacolon, hypovolemia, hypotension, renal dysfunction, colonic perforation with attendant peritonitis, and septic shock.</p>
      </sec>
      <sec id="article-27943.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Initiate stool testing for <italic toggle="yes">C. difficile</italic> when patients have positive guaiac diarrhea in combination with radiographic evidence of toxic megacolon or the presence of&#x000a0;<italic toggle="yes">C. difficile</italic> risk factors such as hospitalization, antibiotic or chemotherapy exposure, and marked leukemoid reactions. Screening for C. difficile as the causative agent for pseudomembranous colitis begins with screening for the<italic toggle="yes"> C. difficile</italic> toxins.&#x000a0;<xref ref-type="bibr" rid="article-27943.r8">[8]</xref><xref ref-type="bibr" rid="article-27943.r9">[9]</xref></p>
        <p>A common lab algorithm utilizes an enzyme immunoassay (EIA) to screen for glutamate dehydrogenase antigen, present in most <italic toggle="yes">C. difficile</italic> isolates followed by EIA sampling for&#x000a0;<italic toggle="yes">C. difficile</italic> toxin A&#x000a0;and toxin B.</p>
        <p>Nucleic acid amplification tests, polymerase chain reaction, loop-mediated isothermal amplification for <italic toggle="yes">C. difficile</italic> have excellent sensitivity and specificity with high positive likelihood ratios; utilization of these assays aids in clarifying discrepancies between glutamate dehydrogenase and EIA toxin results. Nucleic acid amplification tests results should be interpreted with caution because they do not distinguish <italic toggle="yes">C. difficile</italic> colonization from active infection unless testing for concurrent toxin production.&#x000a0;</p>
        <p>Consider initiating testing for <italic toggle="yes">C. difficile</italic> colitis on inpatients having multiple, 3, liquid consistency stools per day. Avoid sending stool samples to test for a cure because assays remain positive in 60% upon completing therapy. With its inherent hazards and monetary fees, endoscopy is not recommended unless clinical suspicion persists despite negative diagnostic testing.</p>
      </sec>
      <sec id="article-27943.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Although only oral vancomycin and fidaxomicin have US Food and Drug Administration approval for treatment of <italic toggle="yes">C. difficile</italic> colitis, metronidazole has remained a first-line agent for four decades. Multiple studies document near the equivalent effect of metronidazole with vancomycin for the initial treatment of mild to moderate<italic toggle="yes"> C. difficile</italic> colitis. Criteria for severe <italic toggle="yes">C. difficile</italic> colitis include: leukemoid reaction greater than 35,000/mm3, hypotension, admission to an intensive care unit, elevated serum lactate, and/or evidence of end-organ damage such as acute kidney injury or delirium; most manifestations of pseudomembranous colitis will signify severe disease. Because of superior cure rates for severe disease, administer oral vancomycin as first-line treatment of&#x000a0;<italic toggle="yes">C. difficile</italic> colitis. With recurrent <italic toggle="yes">C. difficile</italic> colitis after oral vancomycin therapy, consider either fidaxomicin or rifaximin oral administration. For fulminant <italic toggle="yes">C. difficile</italic> pseudomembranous colitis refractory to pharmacological therapy or with complications such as megacolon or colonic perforation, surgical intervention may be warranted, including hemicolectomy. Recurrent<italic toggle="yes"> C. difficile</italic> colitis commonly occurs following initial pharmacologic therapy; usually, the initial antibiotic therapy is reinstituted unless evidence exists of worsening disease severity. With three or more disease recurrences despite therapy with oral vancomycin, fecal microbiota transplant has shown benefit in small trials.<xref ref-type="bibr" rid="article-27943.r10">[10]</xref><xref ref-type="bibr" rid="article-27943.r11">[11]</xref><xref ref-type="bibr" rid="article-27943.r12">[12]</xref></p>
      </sec>
      <sec id="article-27943.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Pseudomembranous colitis from&#x000a0;<italic toggle="yes">C. difficile&#x000a0;</italic>needs to be distinguished from other etiologies of infectious and noninfectious dysentery which include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diverticulitis</p>
          </list-item>
          <list-item>
            <p>Crohn disease</p>
          </list-item>
          <list-item>
            <p>Irritable bowel disease</p>
          </list-item>
          <list-item>
            <p>Salmonella infection</p>
          </list-item>
          <list-item>
            <p>Vibrio infections</p>
          </list-item>
          <list-item>
            <p>Viral and bacterial gastroenteritis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27943.s11" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Colitis</p>
          </list-item>
          <list-item>
            <p>Bowel perforation</p>
          </list-item>
          <list-item>
            <p>Toxic megacolon</p>
          </list-item>
          <list-item>
            <p>Sepsis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27943.s12" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>A sizeable minority of successfully treated <italic toggle="yes">C. difficile</italic> colitis patients will have persistent postinfectious alterations of their bowel habits, similar to irritable bowel syndrome and other functional gastrointestinal disorders. Recrudescent colitis can occur in up to 30% of cases. One challenge of managing recrudescent pseudomembranous colitis involves distinguishing failures to eliminate<italic toggle="yes"> C. difficile</italic>, or at least transforming it into a quiescent phase, from new colonic infections.</p>
      </sec>
      <sec id="article-27943.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>C difficile is not only an annoying infection it can be associated with high morbidity and mortality. Today the emphasis is on prevention. All healthcare workers including nurses and pharmacists need to play a proactive role in preventing C.difficile colitis. When dealing with patients with C.difficile colitis, one should wear gloves and proper washing techniques. All staff and visitors need to be educated about hand hygiene. All hospital surfaces and inanimate objects need to be disinfected including thermometers, bedpans, doorknobs, and sinks. Patients who have a severe infection should be isolated. The pharmacist should regularly assess the need for antibiotics and gastric acid suppressants as these have been associated with severe C.difficile colitis.<xref ref-type="bibr" rid="article-27943.r13">[13]</xref><xref ref-type="bibr" rid="article-27943.r14">[14]</xref><xref ref-type="bibr" rid="article-27943.r15">[15]</xref> (Level V)</p>
        <p>
<bold>Evidence-based Outcomes</bold>
</p>
        <p>Patients with mild C.difficile&#x000a0;colitis usually recover and have a good prognosis. Many of these individuals will only require supportive therapy like hydration. However, those with severe colitis can develop dehydration, electrolyte deficiencies and persistent diarrhea that may last several weeks. In these patients, treatment&#x000a0;is recommended. When treatment is&#x000a0;initiated with metronidazole or vancomycin, the majority of these individuals will improve in 7-10 days. About 20% of patients with C.difficile colitis will relapse after treatment has been completed. Patients who relapse tend to&#x000a0;have recurrent episodes. In severe cases of C.difficile colitis, the hospital stay is prolonged and some develop complications that require immediate surgery. Mortality rates of 3-7% have been reported in many centers.<xref ref-type="bibr" rid="article-27943.r2">[2]</xref><xref ref-type="bibr" rid="article-27943.r16">[16]</xref></p>
      </sec>
      <sec id="article-27943.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27943&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27943">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/pseudomembranous-colitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27943">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27943/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27943">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-27943.s15">
        <fig id="article-27943.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Pseudomembranous colitis image donated by sbhimji</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Pseudomembranous_colitis_1" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-27943.s16">
        <title>References</title>
        <ref id="article-27943.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Curraize</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rousseau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Corvec</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>El-Helali</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Fihman</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Barbut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Collignon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Le Monnier</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Variable spectrum of disease and risk factors of peripartum Clostridium difficile infection: report of 14 cases from French hospitals and literature review.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>2293</fpage>
            <page-range>2293-2299</page-range>
            <pub-id pub-id-type="pmid">30178230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khanafer</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vanhems</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barbut</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Eckert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perraud</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vandenesch</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Luxemburger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Demont</surname>
                <given-names>C</given-names>
              </name>
              <collab>CDI01 Study Group</collab>
            </person-group>
            <article-title>Outcomes of Clostridium difficile-suspected diarrhea in a French university hospital.</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>37</volume>
            <issue>11</issue>
            <fpage>2123</fpage>
            <page-range>2123-2130</page-range>
            <pub-id pub-id-type="pmid">30120646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dicks</surname>
                <given-names>LMT</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Brandsborg</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marcotte</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile, the Difficult "Kloster" Fuelled by Antibiotics.</article-title>
            <source>Curr Microbiol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>76</volume>
            <issue>6</issue>
            <fpage>774</fpage>
            <page-range>774-782</page-range>
            <pub-id pub-id-type="pmid">30084095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prechter</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Stallmach</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>[Clostridium difficile in the intensive care unit].</article-title>
            <source>Med Klin Intensivmed Notfmed</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>115</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-87</page-range>
            <pub-id pub-id-type="pmid">29995234</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sachu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dinesh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Siyad</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vasudevan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Karim</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>A prospective cross sectional study of detection of <italic>Clostridium difficile</italic> toxin in patients with antibiotic associated diarrhoea.</article-title>
            <source>Iran J Microbiol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">29922412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sch&#x000e4;ffler</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Breitr&#x000fc;ck</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title><italic>Clostridium difficile</italic> - From Colonization to Infection.</article-title>
            <source>Front Microbiol</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>646</fpage>
            <pub-id pub-id-type="pmid">29692762</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Papatheodorou</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Barth</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Minton</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Aktories</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Cellular Uptake and Mode-of-Action of Clostridium difficile Toxins.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2018</year>
            <volume>1050</volume>
            <fpage>77</fpage>
            <page-range>77-96</page-range>
            <pub-id pub-id-type="pmid">29383665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wessling</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Radiological imaging of acute infectious and non-infectious enterocolitis].</article-title>
            <source>Radiologe</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>302</fpage>
            <page-range>302-311</page-range>
            <pub-id pub-id-type="pmid">29569035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jessurun</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Differential Diagnosis of Acute Colitis: Clues to a Specific Diagnosis.</article-title>
            <source>Surg Pathol Clin</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>863</fpage>
            <page-range>863-885</page-range>
            <pub-id pub-id-type="pmid">29103537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al Momani</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Abughanimeh</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Boonpheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gabriel</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fidaxomicin vs Vancomycin for the Treatment of a First Episode of Clostridium Difficile Infection: A Meta-analysis and Systematic Review.</article-title>
            <source>Cureus</source>
            <year>2018</year>
            <month>Jun</month>
            <day>11</day>
            <volume>10</volume>
            <issue>6</issue>
            <fpage>e2778</fpage>
            <pub-id pub-id-type="pmid">30112254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>von Braun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>L&#x000fc;bbert</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Treatment of acute and recurrent Clostridium difficile infections : What is new?].</article-title>
            <source>Internist (Berl)</source>
            <year>2018</year>
            <month>May</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>505</fpage>
            <page-range>505-513</page-range>
            <pub-id pub-id-type="pmid">29536125</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>NT</given-names>
              </name>
              <name>
                <surname>Maw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tmanova</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Pino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ancy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis.</article-title>
            <source>Gastroenterology</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>152</volume>
            <issue>8</issue>
            <fpage>1889</fpage>
            <page-range>1889-1900.e9</page-range>
            <pub-id pub-id-type="pmid">28192108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Wilden</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Velmahos</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Bajwa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Finn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Yeh</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>de Moya</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fagenholz</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Effects of a New Hospital-Wide Surgical Consultation Protocol in Patients with Clostridium difficile Colitis.</article-title>
            <source>Surg Infect (Larchmt)</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>563</fpage>
            <page-range>563-569</page-range>
            <pub-id pub-id-type="pmid">28557651</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cruz-Betancourt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Sposato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Milton</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Louzon</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pepe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Girgis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SV</given-names>
              </name>
              <name>
                <surname>Ibrahim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Van Horn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Effects of a predictive preventive model for prevention of Clostridium difficile infection in patients in intensive care units.</article-title>
            <source>Am J Infect Control</source>
            <year>2016</year>
            <month>Apr</month>
            <day>01</day>
            <volume>44</volume>
            <issue>4</issue>
            <fpage>421</fpage>
            <page-range>421-4</page-range>
            <pub-id pub-id-type="pmid">26775936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vassallo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Clostridium difficile: improving the prevention paradigm in healthcare settings.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>12</volume>
            <issue>9</issue>
            <fpage>1087</fpage>
            <page-range>1087-102</page-range>
            <pub-id pub-id-type="pmid">25109301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27943.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Venkat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pandit</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Telemi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trofymenko</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pandian</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Nfonsam</surname>
                <given-names>VN</given-names>
              </name>
            </person-group>
            <article-title>Frailty Predicts Morbidity and Mortality after Colectomy for Clostridium difficile Colitis.</article-title>
            <source>Am Surg</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>628</fpage>
            <page-range>628-632</page-range>
            <pub-id pub-id-type="pmid">29966560</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
